UY25580A1 - Compuestos de beta lactama y su uso como inhibidores de triptasa - Google Patents

Compuestos de beta lactama y su uso como inhibidores de triptasa

Info

Publication number
UY25580A1
UY25580A1 UY25580A UY25580A UY25580A1 UY 25580 A1 UY25580 A1 UY 25580A1 UY 25580 A UY25580 A UY 25580A UY 25580 A UY25580 A UY 25580A UY 25580 A1 UY25580 A1 UY 25580A1
Authority
UY
Uruguay
Prior art keywords
compounds
inhibitors
triptase
lactama
beta
Prior art date
Application number
UY25580A
Other languages
English (en)
Inventor
Gregory S Bisacchi
William A Slusarchyk
Uwe Treuner
James C Sutton
Robert Zahler
David R Kronenthal
Michael E Randazzo
Zhongmin Xu
Zhongping Shi
Mark D Schwinden
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY25580A1 publication Critical patent/UY25580A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta invención se refiere a los nuevos compuestos beta lactama de las fórmulas I, II, III, IV y V (I) y al uso de tales compuestos como inhibidores de varios sistemas de enzima in vivo que incluyen triptasa, trombina, tripsina, factor Xa, factor VIIa y activador de plasminogeno tipo uricinasa.
UY25580A 1998-06-25 1999-06-24 Compuestos de beta lactama y su uso como inhibidores de triptasa UY25580A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9063698P 1998-06-25 1998-06-25

Publications (1)

Publication Number Publication Date
UY25580A1 true UY25580A1 (es) 2001-08-27

Family

ID=22223632

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25580A UY25580A1 (es) 1998-06-25 1999-06-24 Compuestos de beta lactama y su uso como inhibidores de triptasa

Country Status (24)

Country Link
EP (1) EP1089973B1 (es)
JP (1) JP2002518478A (es)
KR (1) KR20010053173A (es)
CN (1) CN1202081C (es)
AR (1) AR018945A1 (es)
AT (1) ATE309211T1 (es)
AU (1) AU752320B2 (es)
BR (1) BR9911373A (es)
CA (1) CA2336003A1 (es)
DE (1) DE69928257T2 (es)
ES (1) ES2249017T3 (es)
HU (1) HUP0104308A3 (es)
ID (1) ID27137A (es)
IL (1) IL140414A0 (es)
NO (1) NO20006380L (es)
NZ (1) NZ507627A (es)
PE (1) PE20000729A1 (es)
PL (1) PL345067A1 (es)
RU (1) RU2211832C2 (es)
TR (1) TR200003859T2 (es)
TW (1) TW548270B (es)
UY (1) UY25580A1 (es)
WO (1) WO1999067215A1 (es)
ZA (1) ZA200006028B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7511159B2 (en) 2003-12-25 2009-03-31 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
WO2006062110A1 (ja) * 2004-12-06 2006-06-15 Banyu Pharmaceutical Co., Ltd. ピペラジン誘導体
JP5846527B2 (ja) * 2010-02-17 2016-01-20 国立大学法人京都大学 ＴＧＦ−βシグナル伝達阻害剤
TW201514143A (zh) * 2013-03-20 2015-04-16 Hoffmann La Roche 新穎脲衍生物
EP2989080A1 (en) 2013-04-22 2016-03-02 Reuter Chemische Apparatebau KG Process for preparing enantiomerically enriched 3-hydroxymethylpiperidine
US9975879B2 (en) 2013-06-04 2018-05-22 Temple University Of The Commonwealth System Of Higher Education Beta lactams as modulators of glutamate uptake and methods for use thereof
CN108892661B (zh) * 2014-02-07 2023-03-14 艾克赛特赫拉制药有限责任公司 治疗化合物和组合物
CN111902404A (zh) 2018-02-07 2020-11-06 艾克赛特赫拉制药有限责任公司 治疗化合物和组合物
WO2019185046A1 (zh) * 2018-03-30 2019-10-03 上海美悦生物科技发展有限公司 四元内酰胺类化合物及其药学用途
CN109988098A (zh) * 2019-05-23 2019-07-09 常州工程职业技术学院 一种(r)-n-叔丁氧羰基-3-羟甲基哌啶的合成方法
WO2020259366A1 (zh) * 2019-06-25 2020-12-30 广东东阳光药业有限公司 一种凝血因子XIa抑制剂的晶型及其制备方法
AU2020378643A1 (en) 2019-11-08 2022-06-02 Coave Therapeutics Modified adeno-associated virus vectors and delivery thereof into the central nervous system
IL302444A (en) * 2020-11-06 2023-06-01 Coave Therapeutics Lactam muscle adeno-associated virus vectors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110812A (en) * 1990-06-04 1992-05-05 Bristol-Myers Squibb Co. Azetidin-2-one derivatives as serine protease inhibitors
US5175283A (en) * 1990-06-04 1992-12-29 Bristol-Myers Squibb Company Azetidin-2-one derivatives as serine protease inhibitors
US5250677A (en) * 1990-06-04 1993-10-05 Bristol-Myers Squibb Company Azetidin-2-one derivatives as serine protease inhibitors
US5037819A (en) * 1990-06-04 1991-08-06 Bristol-Myers Squibb Company Azetidin-2-one derivatives as serine protease inhibitors
US5747485A (en) * 1995-04-13 1998-05-05 Merck & Co., Inc. Substituted azetidiones as anti-inflammatory and antidegenerative agents
DE69711926D1 (de) * 1996-09-23 2002-05-16 Naeja Pharmaceutical Inc 3,4-disubstituierte azetidin-2-on-derivate die als cystein-proteinase regulatoren nuetzlich sind

Also Published As

Publication number Publication date
ES2249017T3 (es) 2006-03-16
WO1999067215A1 (en) 1999-12-29
IL140414A0 (en) 2002-02-10
CA2336003A1 (en) 1999-12-29
NO20006380D0 (no) 2000-12-14
ID27137A (id) 2001-03-01
NZ507627A (en) 2003-12-19
RU2211832C2 (ru) 2003-09-10
TR200003859T2 (tr) 2001-07-23
AU4695099A (en) 2000-01-10
EP1089973A1 (en) 2001-04-11
CN1202081C (zh) 2005-05-18
AR018945A1 (es) 2001-12-12
ATE309211T1 (de) 2005-11-15
PE20000729A1 (es) 2000-10-28
EP1089973A4 (en) 2001-12-12
HUP0104308A3 (en) 2002-06-28
CN1307560A (zh) 2001-08-08
EP1089973B1 (en) 2005-11-09
BR9911373A (pt) 2001-09-18
KR20010053173A (ko) 2001-06-25
DE69928257T2 (de) 2006-08-03
AU752320B2 (en) 2002-09-12
PL345067A1 (en) 2001-12-03
JP2002518478A (ja) 2002-06-25
DE69928257D1 (de) 2005-12-15
HUP0104308A2 (hu) 2002-04-29
TW548270B (en) 2003-08-21
NO20006380L (no) 2000-12-14
ZA200006028B (en) 2002-09-25

Similar Documents

Publication Publication Date Title
UY25580A1 (es) Compuestos de beta lactama y su uso como inhibidores de triptasa
MX9404114A (es) Nuevos derivados de peptidos.
ATE338030T1 (de) Amidine-inhibitoren der serine-proteasen
AR008861A1 (es) COMPUESTOS DE LACTAMA E IMIDA HETEROCICLICOS DE ARALQUILO Y ARALQUILEDENO, COMPUESTOS INTERMEDIARIOS PARA SU SíNTESIS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN.
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
ES2186874T3 (es) Analogos de m-amidinofenilo como inhibidores del factor xa.
PA8446001A1 (es) Derivados de n-hidroxi-b-sulfonilpropionamida
DE60022508D1 (de) Inhibitoren von serin proteasen
UY27986A1 (es) Nuevas quinazolinonas espirocondensadas y su uso c omo inhibidores de la fosfodiesterasa
DE60122718D1 (de) Strukturen und zusammensetzungen zur erhöhung der stabilität von aktiven peroxiden
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
DE60023266D1 (de) Serinprotease-inhibitoren
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
PT970095E (pt) Novos inibidores benzimidazole de frutose-1,6-bisfosfatase
IL222773B (en) Biaryl compounds, pharmaceutical preparations containing them, use of such compounds for the manufacture of drugs and in vitro methods and devices using such compounds
ES2168737T3 (es) Inhibidores de la oxido nitrico sintasa.
DE69819349D1 (de) 1-amino-7-isochinolin-derivate als serin protease inhibitoren
BR9713338A (pt) Benzonaftiridinas como terapêuticos brÈnquicos.
CO4940451A1 (es) Derivados de acido barbiturico con actividad antimetastica y antitumoral
PA8506301A1 (es) Cristal de 4- carboxamino- 1,2,3,4,- tetrahidroquinolina 2-sustituida
DK0975327T3 (da) Anvendelse af 5HT3-antagonister til befordring af tarmudskylning
TR200101779T2 (tr) Yeni bisiklik bileşenler
DK1032414T3 (da) Kombination af inhibitor for angiotensinomdannende enzym med et diuretikum til behandling af forstyrrelser i mikrokredsløbet
ES2194083T3 (es) Utilizacion en una composicion como activador y/o estabilizador de ciclooxigenasa de al menos un derivado de pirimidina sustituido en 6.
BR9810570A (pt) Composição farmacêutica, e, uso de inibidor de aldose redutase e um inibidor de enzima de conversão de angiotensina

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20110406